Active Perforin 1 (PRF1) Mus musculus (Mouse) Active protein

FLH2; HPLH2; P1; PFP; Pore Forming Protein; Cytolysin; Lymphocyte pore-forming protein

No quotes Distributors
Overview
Properties
  • Buffer FormulationPBS, pH7.4, containing 0.01% SKL, 5% Trehalose.
  • Traits Freeze-dried powder, Purity > 80%
  • Isoelectric Point8.0
Share your citation Upload your experimental result Review Leave a message
Loading...

Share a new citation as an author

Upload your experimental result

Review

Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

Name*
Organization
Address
E-mail address*
Telephone
Inquiry*
Verification code* CheckCode
  • Active Perforin 1 (PRF1) Packages (Simulation)
  • Active Perforin 1 (PRF1) Packages (Simulation)
  • APB317Mu03.jpg Figure. SDS-PAGE
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

Usage

Reconstitute in 10mM PBS (pH7.4) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

Storage

Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

Stability

The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

Citations

  • Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfectionPubmed:26915636
  • The immunoregulatory effects of CD8 T-cell–derived perforin on diet-induced nonalcoholic steatohepatitisPubmed: 30951375
  • A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumorsPubmed: 31695790
  • CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protectionPubmed: 33223223
  • Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumorsPubmed: 32772342
  • Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma34377237
  • Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy34873307
  • Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusionPubmed:35061012

Recommend products